X-Chem Services Empower Your Drug Discovery Strategy
Our DNA-encoded library (DEL) expertise, medicinal chemistry experience and artificial intelligence innovations position X-Chem as the premier service provider in small molecule drug discovery. You can partner with X-Chem to quickly and efficiently discover molecules which will lead to therapeutic breakthroughs. From tractability assessment to hit-to-lead, from hit ID to lead optimization. Let X-Chem be your trusted partner for access to exceptional scientists and innovative technologies which accelerate the delivery of high-quality clinical candidates.
DEL Screening Services Overview
With more than a decade of experience conducting DEL screening for many target classes, X-Chem is the partner you need to unlock exponential possibilities in your small molecule drug discovery. We wield a vast index of molecules and proprietary tagging approaches. This reach enables you to investigate a hugely diverse range of molecules that hold enormous potential.
We are the recognized leaders in DEL, with an 80% success rate and a track record of over 90 licensed programs covering a wide range of target classes, using our extensive collection of DEL screening libraries comprised of over 250 billion compounds.
HITMiner unlocks the power of DEL data via ArtemisAI to identify additional hits from any catalog, allowing immediate progression of the project during off-DNA synthesis. Find more hits, faster, by training predictive AI models with high-quality DEL data.
DELvalent
DELvalent
DELvalent
DELenable
X-Chem’s DEL screening advantages
- Selections require small quantities of target protein
- Selections are conducted with many conditions in parallel
- Multiplexed selections reveal potency, selectivity, specificity and MOA of hits
- Structure activity-relationship (SAR) data emerges directly from the screen
- Jump-start your hit-to-lead optimization
- Flexible approach including covalent and non-covalent hit identification
Employ X-Chem’s industry-leading medicinal chemistry expertise, empowered by AI, to progress your drug program from hit to candidate at unparalleled speed. Backed by a widely published scientific leadership team with over 20 years of experience in major pharma driving drug discovery, results include:
- >100 patents
- 17 compounds advanced to IND-enabling tox
- 7 compounds reaching Phase I or beyond